Government-Owned Inventions; Availability for Licensing, 43148 [2019-17868]

Download as PDF 43148 Federal Register / Vol. 84, No. 161 / Tuesday, August 20, 2019 / Notices Terry Clark, Office of the Secretary, Paperwork Reduction Act Reports Clearance Officer. [FR Doc. 2019–17886 Filed 8–19–19; 8:45 am] BILLING CODE 4150–29–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Potential Commercial Applications • Target identification in B and T cell deficiency, macrophage defects and hematopoiesis. • A tool for investigating IRF8 mediated issues associated with inflammation and autoimmunity. • Investigative tool for development of potential therapeutics for lymphoma and Human Chronic Myeloid Leukemia. National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240–627–3705 or Chris.Kornak@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Technology description follows: jbell on DSK3GLQ082PROD with NOTICES Floxed Targeted Mouse Strain for Use in Conditional Deletion of the Irf8 Gene Description of Technology IRF8, a member of interferon regulatory factor (IRF) family of transcription factors is a novel intrinsic transcriptional inhibitor of TH17-cell differentiation. TH17-cells are believed to be involved in the pathogenesis of various autoimmune/inflammatory diseases. The Irf8f floxed targeted mutated mouse strain can be used to selectively ablate expression of IRF8 in any cell type in which a Cre recombinase gene is activated. This will permit the identification of IRF8regulated genes and their effects in specific types of developing and mature cells. These materials could be used to help define patterns of gene expression important for the development and function of cells including possible contributions to understanding: Normal VerDate Sep<11>2014 20:49 Aug 19, 2019 Jkt 247001 immune responses, inflammatory conditions, autoimmunity and anti-viral responses. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Competitive Advantages • Mice with established germ line transmission for use in conditional deletion of the IRF8 gene in any cell type. Development Stage • Research Use. Inventors: Herbert Carpenter Morse III (NIAID). Publications: Ouyang, Xinshou, et al. ‘‘Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation.’’ Nature Communications 2, Article number: 314 (2011). Licensing Contact: To license this technology, please contact Chris Kornak at 240–627–3705 or Chris.Kornak@ nih.gov, and reference E–062–2012–0. Dated: August 6, 2019. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2019–17868 Filed 8–19–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD19/CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 Patents and Patent Applications listed in the Supplementary Information section of this Notice to Lyell Immunopharma, Inc. (‘‘Lyell’’), located in South San Francisco, CA. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before September 19, 2019 will be considered. ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jim Knabb, Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850– 9702; Telephone: (240)–276–7856; Facsimile: (240)–276–5504; Email: jim.knabb@nih.gov. SUPPLEMENTARY INFORMATION: Intellectual Property E–016–2015: Chimeric Antigen Receptor Targeting both CD19 and CD22 1. U.S. Provisional Patent Application 62/135,442, filed March 19, 2015 (E– 106–2015–0–US–01); 2. International Patent Application PCT/US2016/023055, filed March 18, 2016 (E–106–2015/0–PCT–02) 3. U.S. Patent Application No.: 15/ 559,485, filed September 19, 2017 (E– E–106–2015/0–US–03) E–017–2017: CD19/CD22 Bicistronic CAR Targeting Human B-Cell Malignancies 1. U.S. Provisional Patent Application 62/506,268, filed May 15, 2017 (E–017– 2017–0–US–01); 2. International Patent Application PCT/US2018/032,809, filed May 15, 2018 (E–017–2017/0–PCT–02) The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following: An exclusive license to: ‘‘Treatment of B cell malignancies using autologously-derived T cell expressing chimeric antigen receptor(s) (CAR) specific for both CD19 and CD22 utilizing the anti-CD19 antigen binding domain of the FM63 antibody and the antiCD22 antigen binding domain of the M971 antibody.’’ The proposed territory is worldwide. This technology discloses CAR therapies that target both CD19 and CD22 by utilizing the anti-CD19 binder E:\FR\FM\20AUN1.SGM 20AUN1

Agencies

[Federal Register Volume 84, Number 161 (Tuesday, August 20, 2019)]
[Notices]
[Page 43148]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17868]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240-627-3705 or 
[email protected]. Licensing information may be obtained by 
communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Floxed Targeted Mouse Strain for Use in Conditional Deletion of the 
Irf8 Gene

Description of Technology

    IRF8, a member of interferon regulatory factor (IRF) family of 
transcription factors is a novel intrinsic transcriptional inhibitor of 
TH17-cell differentiation. TH17-cells are believed to be involved in 
the pathogenesis of various autoimmune/inflammatory diseases. The Irf8f 
floxed targeted mutated mouse strain can be used to selectively ablate 
expression of IRF8 in any cell type in which a Cre recombinase gene is 
activated. This will permit the identification of IRF8-regulated genes 
and their effects in specific types of developing and mature cells. 
These materials could be used to help define patterns of gene 
expression important for the development and function of cells 
including possible contributions to understanding: Normal immune 
responses, inflammatory conditions, autoimmunity and anti-viral 
responses.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications

     Target identification in B and T cell deficiency, 
macrophage defects and hematopoiesis.
     A tool for investigating IRF8 mediated issues associated 
with inflammation and autoimmunity.
     Investigative tool for development of potential 
therapeutics for lymphoma and Human Chronic Myeloid Leukemia.

Competitive Advantages

     Mice with established germ line transmission for use in 
conditional deletion of the IRF8 gene in any cell type.

Development Stage

     Research Use.
    Inventors: Herbert Carpenter Morse III (NIAID).
    Publications: Ouyang, Xinshou, et al. ``Transcription factor IRF8 
directs a silencing programme for TH17 cell differentiation.'' Nature 
Communications 2, Article number: 314 (2011).
    Licensing Contact: To license this technology, please contact Chris 
Kornak at 240-627-3705 or [email protected], and reference E-062-
2012-0.

    Dated: August 6, 2019.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2019-17868 Filed 8-19-19; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.